GlassScriptPhysician profile
Charles I Saperstein
NPI 1780789826
$24,800.08
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $5,734 · 2021: $2,497 · 2022: $2,826 · 2023: $1,675 · 2024: $54.09.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,729.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,729.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $13,907.76 | 2019-2023 | Rinvoq, Linzess, Viberzi |
| Allergan, INC. | $4,666.36 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,215.60 | 2019-2023 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $786.50 | 2019-2023 | Remicade, Simponi, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $710.38 | 2019-2023 | Entyvio |
| Alfasigma USA, INC. | $648.49 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $502.35 | 2020-2023 | Dificid |
| Pfizer INC. | $466.41 | 2019-2023 | |
| Celgene Corporation | $274.43 | 2021-2023 | Zeposia |
| Gilead Sciences, INC. | $254.52 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $206.20 | 2020-2023 | |
| Ardelyx, INC. | $107.65 | 2022-2023 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $104.71 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $104.08 | 2023 | Zeposia |
| Qol Medical, LLC | $101.70 | 2021-2023 | Sucraid |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $98.91 | 2019-2023 | Rebyota |
| Romark Laboratories, Lc | $93.69 | 2019 | |
| Lucid Diagnostics INC. | $81.10 | 2021 | |
| Ucb, INC. | $73.80 | 2019-2020 | |
| Intra-Sana Laboratories | $68.00 | 2022-2023 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Redhill Biopharma INC. | $49.82 | 2020-2022 | |
| Intercept Pharmaceuticals, INC. | $48.09 | 2020-2022 | |
| Medtronic, INC. | $36.37 | 2021-2023 | Pillcam |
| Abbott Laboratories | $27.06 | 2024 | Proclaim |
| Organon LLC | $27.03 | 2024 | |
| Ethicon US, LLC | $25.57 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $21.85 | 2022 | |
| Braintree Laboratories, INC. | $21.51 | 2023 | Suflave |
| Shionogi INC | $17.97 | 2019 | |
| Daiichi Sankyo INC. | $14.24 | 2022 | |
| Digestive Care, INC. | $13.95 | 2020 | |
| Olympus America INC. | $12.46 | 2021 | |
| Shire North American Group INC | $11.52 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$44,503.96 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Saperstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.